Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1999 1
2000 1
2002 1
2004 1
2006 1
2007 1
2008 3
2009 3
2010 1
2011 2
2012 4
2013 3
2014 6
2015 3
2016 1
2017 3
2018 1
2019 2
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
PD-L1 expression in triple-negative breast cancer.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. Mittendorf EA, et al. Among authors: akcakanat a. Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10. Cancer Immunol Res. 2014. PMID: 24764583 Free PMC article.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Xing Y, et al. Among authors: akcakanat a. Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8. Breast Cancer Res. 2019. PMID: 31277699 Free PMC article. Clinical Trial.
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Hassan B, et al. Among authors: akcakanat a. Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Surg Oncol Clin N Am. 2013. PMID: 24012393 Free PMC article. Review.
MK-2206 window of opportunity study in breast cancer.
Akcakanat A, Meric-Bernstam F. Akcakanat A, et al. Ann Transl Med. 2018 Nov;6(Suppl 1):S57. doi: 10.21037/atm.2018.10.32. Ann Transl Med. 2018. PMID: 30613632 Free PMC article. No abstract available.
Targeting translation initiation in breast cancer.
Akcakanat A, Hong DS, Meric-Bernstam F. Akcakanat A, et al. Translation (Austin). 2014 Apr 29;2(1):e28968. doi: 10.4161/trla.28968. eCollection 2014. Translation (Austin). 2014. PMID: 26779407 Free PMC article. Review.
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. Owusu-Brackett N, et al. Among authors: akcakanat a. Oncotarget. 2019 Aug 20;10(49):5011-5019. doi: 10.18632/oncotarget.27082. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489111 Free PMC article.
Targeting PI3K/mTOR signaling in cancer.
Emerling BM, Akcakanat A. Emerling BM, et al. Among authors: akcakanat a. Cancer Res. 2011 Dec 15;71(24):7351-9. doi: 10.1158/0008-5472.CAN-11-1699. Epub 2011 Oct 10. Cancer Res. 2011. PMID: 21987725 Free article.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. Evans KW, et al. Among authors: akcakanat a. Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615. Clin Cancer Res. 2017. PMID: 29093017 Free PMC article.
43 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page